RNA Sequencing Analysis of Patients with Chronic Hepatitis B Treated Using PEGylated Interferon.

IF 2.1 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

International Journal of General Medicine Pub Date : 2024-10-01 eCollection Date: 2024-01-01 DOI:10.2147/IJGM.S474284

Shao-Long Chen, Yao-Jie Shen, Guo-Zhi Chen

{"title":"RNA Sequencing Analysis of Patients with Chronic Hepatitis B Treated Using PEGylated Interferon.","authors":"Shao-Long Chen, Yao-Jie Shen, Guo-Zhi Chen","doi":"10.2147/IJGM.S474284","DOIUrl":null,"url":null,"abstract":"Purpose: Worldwide, chronic hepatitis B virus (CHB) infection is a public health concern, ultimately leading to liver cirrhosis and hepatocellular carcinoma. Currently, patients with CHB can be treated using polyethylene glycol (PEG)ylated interferon (PEG-IFN) antiviral therapy, which has both immune modulatory and antiviral properties. This study aimed to reveal the mechanism underlying the effect of PEG-IFN therapy, to rationally optimize this therapeutic option.Patients and methods: Ten patients with CHB who were positive for the hepatitis B virus e antigen (HBeAg) and were receiving PEG-IFN treatment were enrolled. Clinical and virological parameters were monitored during 48 weeks of treatment. In addition, peripheral blood mononuclear cells (PBMCs) were collected from the 10 patients at 0, 24, and 36 weeks. RNA sequencing technology was used to analyze the RNA expression profile in the PBMC samples.Results: Following PEG-IFN treatment, we identified 217 differentially expressed genes (DEGs), most of which were upregulated. Gene ontology enrichment analysis of the DEGs revealed that they were enriched in 29 clusters, mainly associated with \"antiviral defense\", \"innate immunity\", \"immunity\", \"defense response to virus\", \"response to virus\", \"type I interferon signaling pathway\", \"negative regulation of viral genome replication\", \"innate immune response\", and \"RNA-binding\".Conclusion: After PEG-IFN treatment, a certain mRNA expression profile was observed in patients with CHB, providing further mechanistic insights into the antiviral effect of this therapy.","PeriodicalId":14131,"journal":{"name":"International Journal of General Medicine","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11453141/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of General Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/IJGM.S474284","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Worldwide, chronic hepatitis B virus (CHB) infection is a public health concern, ultimately leading to liver cirrhosis and hepatocellular carcinoma. Currently, patients with CHB can be treated using polyethylene glycol (PEG)ylated interferon (PEG-IFN) antiviral therapy, which has both immune modulatory and antiviral properties. This study aimed to reveal the mechanism underlying the effect of PEG-IFN therapy, to rationally optimize this therapeutic option.

Patients and methods: Ten patients with CHB who were positive for the hepatitis B virus e antigen (HBeAg) and were receiving PEG-IFN treatment were enrolled. Clinical and virological parameters were monitored during 48 weeks of treatment. In addition, peripheral blood mononuclear cells (PBMCs) were collected from the 10 patients at 0, 24, and 36 weeks. RNA sequencing technology was used to analyze the RNA expression profile in the PBMC samples.

Results: Following PEG-IFN treatment, we identified 217 differentially expressed genes (DEGs), most of which were upregulated. Gene ontology enrichment analysis of the DEGs revealed that they were enriched in 29 clusters, mainly associated with "antiviral defense", "innate immunity", "immunity", "defense response to virus", "response to virus", "type I interferon signaling pathway", "negative regulation of viral genome replication", "innate immune response", and "RNA-binding".

Conclusion: After PEG-IFN treatment, a certain mRNA expression profile was observed in patients with CHB, providing further mechanistic insights into the antiviral effect of this therapy.

查看原文本刊更多论文

使用聚乙二醇干扰素治疗慢性乙型肝炎患者的 RNA 测序分析

目的：在全球范围内，慢性乙型肝炎病毒（CHB）感染是一个公共卫生问题，最终会导致肝硬化和肝细胞癌。目前，CHB 患者可以使用聚乙二醇（PEG）化干扰素（PEG-IFN）抗病毒疗法进行治疗，该疗法具有免疫调节和抗病毒的双重特性。本研究旨在揭示PEG-IFN疗法的作用机制，从而合理优化这一治疗方案：十名乙型肝炎病毒 e 抗原（HBeAg）阳性并正在接受 PEG-IFN 治疗的慢性乙型肝炎患者。在 48 周的治疗期间对临床和病毒学参数进行了监测。此外，还在 0 周、24 周和 36 周收集了 10 名患者的外周血单核细胞（PBMC）。采用 RNA 测序技术分析 PBMC 样本中的 RNA 表达谱：结果：PEG-IFN 治疗后，我们发现了 217 个差异表达基因（DEGs），其中大部分基因表达上调。对这些 DEGs 的基因本体富集分析表明，它们富集在 29 个群组中，主要与 "抗病毒防御"、"先天免疫"、"免疫"、"对病毒的防御反应"、"对病毒的反应"、"I 型干扰素信号通路"、"病毒基因组复制的负调控"、"先天免疫反应 "和 "RNA 结合 "有关：结论：PEG-IFN治疗后，在CHB患者中观察到了一定的mRNA表达谱，进一步揭示了该疗法的抗病毒作用机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of General Medicine Medicine-General Medicine

自引率

0.00%

发文量

1113

审稿时长

16 weeks

期刊介绍： The International Journal of General Medicine is an international, peer-reviewed, open access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies across all disease areas. A key focus of the journal is the elucidation of disease processes and management protocols resulting in improved outcomes for the patient. Patient perspectives such as satisfaction, quality of life, health literacy and communication and their role in developing new healthcare programs and optimizing clinical outcomes are major areas of interest for the journal. As of 1st April 2019, the International Journal of General Medicine will no longer consider meta-analyses for publication.